DR. HELEN VLASSARA, MD
Osteopathic Medicine at Gustave L Levy Pl, New York, NY
License number
New York 1402141
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
1 Gustave L Levy Pl #1460, New York, NY 10029
Phone
(212) 241-6447
Personal information
See more information about HELEN VLASSARA at radaris.comName
Address
Phone
201 E 79Th St APT 12C, New York, NY 10075
201 E 79Th St, New York, NY 10075
New York, NY
Shelter Island, NY
1775 York Ave, New York, NY 10128
Organization information
See more information about HELEN VLASSARA at bizstanding.comHelen Vlassara MD
201 E 79 St APT 12C, New York, NY 10075
Industry:
Internist
Phone:
(212) 737-6990 (Phone)
Helen Vlassara
Categories:
Endocrinology & Metabolism Physicians & Surgeons, Internal Medicine Physicians & Surgeons
Professional information
See more information about HELEN VLASSARA at trustoria.com
Dr. Helen Vlassara, New York NY - MD (Doctor of Medicine)
Dr. Helen Vlassara, New York NY - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Diabetes Medicine
Address:
1 Gustave L Levy Pl SUITE 1460, New York 10029
(212) 241-6447 (Phone)
(212) 241-6447 (Phone)
Languages:
English
Monitoring Metabolic Control In Diabetic Patients By Measuring Glycosylated Amino Acids And Peptides In Urine
Monitoring Metabolic Control In Diabetic Patients By Measuring Glycosylated Amino Acids And Peptides In Urine
US Patent:
4371374, Feb 1, 1983
Filed:
Nov 17, 1980
Appl. No.:
6/207471
Inventors:
Anthony Cerami - Flanders NJ
Michael Brownlee - New York NY
Helen Vlassara - New York NY
Michael Brownlee - New York NY
Helen Vlassara - New York NY
Assignee:
The Rockefeller University - New York NY
International Classification:
G01N 3350
US Classification:
23230B
Abstract:
A method of monitoring metabolic control in a diabetes patient comprising measuring the amount of non-enzymatic glycosylated amino acids and peptides in urine of the patient; a method of measurement and a test kit for the measurement are disclosed.
Method And Agents For Removing Advanced Glycosylation Endproducts
Method And Agents For Removing Advanced Glycosylation Endproducts
US Patent:
5811075, Sep 22, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/487398
Inventors:
Helen Vlassara - New York NY
Michael Brownlee - New York NY
Anthony Cerami - Shelter Island NY
Michael Brownlee - New York NY
Anthony Cerami - Shelter Island NY
Assignee:
The Rockefeller University - New York NY
International Classification:
A61K 4900, C12Q 100
US Classification:
424 91
Abstract:
The present invention relates to a method and associated agents for the inhibition and treatment of protein aging in animals by stimulating the bodies of the animals to increase their recognition and affinity for advanced glycosylation end products. Specifically, the method contemplates the administration of certain agents such as advanced glycosylation endproducts, such endproducts as are bound to the carrier, monokines that stimulate phagocytic cells to increase their activity toward advanced glycosylation endproducts, and mixtures of these materials either alone, or in conjunction with other co-stimulatory agents. Numerous diagnostic and therapeutic applications are defined, and pharmaceutical compositions are also contemplated.
Inhibition Of Tnf-Alpha Induced Activation Of Nfkb By Pentosan Polysulfate
Inhibition Of Tnf-Alpha Induced Activation Of Nfkb By Pentosan Polysulfate
US Patent:
2013014, Jun 6, 2013
Filed:
Jan 14, 2011
Appl. No.:
13/522441
Inventors:
Gary E. Striker - New York NY, US
Helen Vlassara - New York NY, US
Feng Zheng - Middle Village NY, US
Helen Vlassara - New York NY, US
Feng Zheng - Middle Village NY, US
Assignee:
MOUNT SINAI SCHOOL OF MEDICINE - New York NY
International Classification:
A61K 31/737, C12Q 1/02
US Classification:
514 54, 435184, 435 612, 506 10
Abstract:
Oral pentosan polysulfate (PPS) compositions treat diseases such as diabetes, inflammation, atherosclerosis. The compositions are also effective in reducing matrix metalloproteinases (MMPs).
Method And Agents For Removing Advanced Glycosylation Endproducts
Method And Agents For Removing Advanced Glycosylation Endproducts
US Patent:
4900747, Feb 13, 1990
Filed:
Sep 3, 1987
Appl. No.:
7/091534
Inventors:
Helen Vlassara - New York NY
Michael Brownlee - New York NY
Anthony Cerami - Shelter Island NY
Michael Brownlee - New York NY
Anthony Cerami - Shelter Island NY
Assignee:
The Rockefeller University - New York NY
International Classification:
A61K 31415
US Classification:
514402
Abstract:
The present invention relates to a method and associated agents for the inhibition and treatment of protein aging in animals by stimulating the bodies of the animals to increase their recognition and affinity for advanced glycosylation end products. Specifically, the method contemplates the administration of certain agents such as advanced glycosylation endproducts, such endproducts as are bound to the carrier, monokines that stimulate phagocytic cells to increase their activity toward advanced glycosylation endproducts, and mixtures of these materials either alone, or in conjunction with other co-stimulatory agents. Numerous diagnostic and therapeutic applications are defined, and pharmaceutical compositions are also contemplated.
Liver-Derived Receptors For Advanced Glycosylation Endproducts And Uses Thereof
Liver-Derived Receptors For Advanced Glycosylation Endproducts And Uses Thereof
US Patent:
5585344, Dec 17, 1996
Filed:
Aug 23, 1991
Appl. No.:
7/749438
Inventors:
Helen Vlassara - New York NY
Zhi Yang - Palo Alto CA
Anthony Cerami - Shelter Island NY
Zhi Yang - Palo Alto CA
Anthony Cerami - Shelter Island NY
Assignee:
The Rockefeller University - New York NY
International Classification:
C07K 14705, A61K 3817
US Classification:
514 2
Abstract:
The present invention relates to receptors for advanced glycosylation endproducts derived from rat liver membranes, and that specifically comprise proteins determined to possess molecular masses of about 90 kD and 60 kD, respectively, as assessed by migration during SDS-PAGE. Partial N-terminal sequences have been determined and diagnostic and therapeutic agents, compositions and methods are proposed.
In Vitro Assay Of Mesangial Cell-Derived Receptors For Advanced Glycosylation Endproducts
In Vitro Assay Of Mesangial Cell-Derived Receptors For Advanced Glycosylation Endproducts
US Patent:
5316754, May 31, 1994
Filed:
Jan 28, 1993
Appl. No.:
8/010268
Inventors:
Helen Vlassara - New York NY
Anthony Cerami - Shelter Island NY
Anthony Cerami - Shelter Island NY
Assignee:
The Rockefeller University - New York NY
International Classification:
C07K 300, C12Q 100, A01N 3752, A61K 31155
US Classification:
424 2
Abstract:
The present invention relates to a method and associated agents for measuring the presence and amount of advanced glycosylation endproducts in cells and fluids. The methods take advantage of the existence of receptors and receptor complexes for AGEs and include receptor-containing ligands comprising whole mesangial and other cells, mesangial cellular fragments and protein extracts therefrom. Competitive assays, sandwich assays and assays involving AGE antisera are disclosed. Numerous diagnostic applications are defined and test kits are also contemplated.
Mesangial Cell-Derived Receptors For Advanced Glycosylation Endproducts And Uses Thereof
Mesangial Cell-Derived Receptors For Advanced Glycosylation Endproducts And Uses Thereof
US Patent:
5202424, Apr 13, 1993
Filed:
Aug 23, 1991
Appl. No.:
7/749444
Inventors:
Helen Vlassara - New York NY
Anthony Cerami - Shelter Island NY
Anthony Cerami - Shelter Island NY
Assignee:
The Rockefeller University - New York NY
International Classification:
C07K 300, C12Q 100, A01N 3752, A61K 31155
US Classification:
530395
Abstract:
The present invention relates to a method and associated agents for measuring the presence and amount of advanced glycosylation endproducts in cells and fluids. The methods take advantage of the existence of receptors and receptor complexes for AGEs and include receptor-containing ligands comprising whole mesangial and other cells, mesangial cellular fragments and protein extracts therefrom. Competitive assays, sandwich assays and assays involving AGE antisera are disclosed. Numerous diagnostic applications are defined and test kits are also contemplated.